A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.

Authors

Shou Y Yaping , Robinson DM Douglas M , Amakye DD Dereck D , Rose KL Kristine L , Cho YJ Yoon-Jae , Ligon KL Keith L , Sharp T Thad , Haider AS Asifa S , Bandaru R Raj , Ando Y Yuichi , Geoerger B Birgit , Doz F François , Ashley DM David M , Hargrave DR Darren R , Casanova M Michela , Tawbi HA Hussein A , Rodon J Jordi , Thomas AL Anne L , Mita AC Alain C , MacDonald TJ Tobey J , Kieran MW Mark W .
Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 2 1; 21(3).
585-93

Abstract

Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pathway-activated medulloblastoma.

Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. We identified and clinically validated a five-gene Hh signature assay that can be used to preselect patients with Hh pathway-activated medulloblastoma.